C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H1 2019

You are here: 麻豆原创 Catalog Pharma & Healthcare Drug Pipeline

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H1 2019

麻豆原创 Research Report Summary

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H1 2019 report is published on April 29, 2019 and has 68 pages in it. This market research report provides information about Drug Pipeline, Pharma & Healthcare industry. It covers Global market data and forecasts. It is priced starting at USD 3,500.00 for Single User License (PDF) which allows one person to use this report.

Please read the description and table of contents of this research report given below to check whether it meets your research requirements. If not, then please do not hesitate to contact us using "Report Enquiry" form given below. We can customize this research report or suggest a new fully customized market research report to meet your research goals and data requirements.

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H1 2019

Printer version

Send by email

Publication ID:听

GMD0419071

Publication Date:听

April 29, 2019

笔补驳别蝉:听

68

笔耻产濒颈蝉丑别谤:听

Global 麻豆原创s Direct

颁辞耻苍迟谤颈别蝉:听

Global

USD 3,500.00

Pay By Invoice

If you wish to purchase this report using bank/wire transfer against an invoice, please fill your details using request invoice form given below.

Globally Trusted Brand

We help executives from firms听to Start-ups听with their market research needs thus听we can help you too.听

Secure Checkout

You can shop confidently as your online payments are processed using PCI DSS compliant secure payment gateways on our website.

Frequently Asked Questions

If you have any pre-sales听questions related to this report please let us know using the "Report Enquiry" form below. This will help us provide you听with answers听so that you can purchase with confidence. If you wish to read about frequently asked questions by our customers please visit our .

Tabs

Description

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H1 2019

Summary

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report C5a Anaphylatoxin Chemotactic Receptor 1 - Pipeline Review, H1 2019, outlays comprehensive information on the C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Complement component 5a receptor 1 (C5AR1) or CD88 is a G protein-coupled receptor for C5a. It functions as a complement receptor. Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production. The molecules developed by companies in Filing rejected/Withdrawn, Phase I, Preclinical and Discovery stages are 1, 1, 6 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Immunology, Gastrointestinal, Oncology, Dermatology, Genito Urinary System And Sex Hormones, Infectious Disease, Mouth and Dental Disorders, Musculoskeletal Disorders and Respiratory which include indications Alzheimer's Disease, Autoimmune Disorders, Allergic Asthma, Amyotrophic Lateral Sclerosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Arthritis, Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), Churg-Strauss Syndrome, Glomerulonephritis, Granulomatosis with Polyangiitis (Wegener's Granulomatosis), Hepatocellular Carcinoma, Hidradenitis Suppurativa, Huntington Disease, Inflammatory Bowel Disease, Inflammatory Pain, Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Microscopic Polyangiitis (MPA), Motor Neuron Diseases, Neuroinflammation, Neuropathic Pain (Neuralgia), Non-Small Cell Lung Cancer, Pain, Periodontitis and Rheumatoid Arthritis.

Furthermore, this report also reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)
- The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics and enlists all their major and minor projects
- The report assesses C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it鈥檚 most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents
List of Tables
List of Figures
Introduction
Global 麻豆原创s Direct Report Coverage
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Overview
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Companies Involved in Therapeutics Development
AFFiRiS AG
ChemoCentryx Inc
Dompe Farmaceutici SpA
Innate Pharma SA
Integral Molecular Inc
MorphoSys AG
Prommune Inc
Teva Pharmaceutical Industries Ltd
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Drug Profiles
ALS-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DF-2593A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize C5aR for Periodontitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-67 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPH-5401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Antagonize C5AR1 for Immunological Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOR-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMX-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize CD88 for Musculoskeletal, Gastrointestinal, Autoimmune and Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target C5a for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Dormant Products
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Discontinued Products
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Product Development Milestones
Featured News & Press Releases
Jan 24, 2019: ChemoCentryx announces withdrawal of phase II-based conditional marketing authorisation (CMA) application for ANCA-associated vasculitis in Europe, phase III advocate trial data release planned for Q4 2019
Oct 25, 2018: ChemoCentryx announces presentation of data on Avacopan, a complement 5a receptor inhibitor, at ASN Kidney Week 2018
Sep 12, 2018: Innate pharma announces enrollment of first patient in the Phase I study of IPH5401 in combination with durvalumab (Imfinzi) in solid tumors
May 23, 2018: ChemoCentryx Announces Presentation On Avacopan at the 55th ERA-EDTA Congress
Apr 11, 2018: ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting
Jan 04, 2018: Avacopan Conditional 麻豆原创ing Authorization Application Accepted for Regulatory Review by European Medicines Agency
Nov 03, 2017: ChemoCentryx Presents Data On Avacopan at ASN Kidney Week 2017
Sep 11, 2017: Innate Pharma Presents New Preclinical Data For IPH5401 at 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy conference
Jun 06, 2017: Oral Presentation at ERA-EDTA Congress Highlighst Fourth Potential Indication for Avacopan
May 23, 2017: ChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy
Mar 22, 2017: ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy
Jan 09, 2017: ChemoCentryx Provides Update on Lead Program Avacopan
Nov 07, 2016: ChemoCentryx Announces Presentations of Positive Results from Phase II ANCA-Associated Vasculitis Trials (鈥楥LEAR鈥� and 鈥楥LASSIC鈥�) of Orally Administered Complement 5a Receptor Inhibitor CCX168 (鈥楢vacopan鈥�)
Oct 27, 2016: ChemoCentryx Reports Improvement in Renal Physiology and Stabilization of Kidney Function Following Treatment with Orally Administered Complement Inhibitor CCX168 (Avacopan) in Patient with Refractory C3 Glomerulopathy
Oct 17, 2016: ChemoCentryx Announces Presentation of Positive Data from Ongoing Pilot Phase II Trial of CCX168 (Avacopan) in Atypical Hemolytic Uremic Syndrome at ASN Kidney Week 2016
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
List of Tables
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by AFFiRiS AG, H1 2019
Pipeline by ChemoCentryx Inc, H1 2019
Pipeline by Dompe Farmaceutici SpA, H1 2019
Pipeline by Innate Pharma SA, H1 2019
Pipeline by Integral Molecular Inc, H1 2019
Pipeline by MorphoSys AG, H1 2019
Pipeline by Prommune Inc, H1 2019
Pipeline by Teva Pharmaceutical Industries Ltd, H1 2019
Dormant Products, H1 2019
Dormant Products, H1 2019 (Contd..1), H1 2019
Discontinued Products, H1 2019

List of Figures
List of Figures
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

Companies Covered

AFFiRiS AG
ChemoCentryx Inc
Dompe Farmaceutici SpA
Innate Pharma SA
Integral Molecular Inc
MorphoSys AG
Prommune Inc
Teva Pharmaceutical Industries Ltd

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Enquiry / Request Invoice

Report Inquiry

Do you have more questions related to this market research report after going through the description and table of contents?

We are here to help. Please use the form given below to let us know your questions related to this report.

Kindly use your official email address and contact number to ensure speedy response.

First Name *

Last Name *

Company *

Email Address *

Phone (Including International Code) *

Report Title *

Do you need invoice for purchasing this report? *

Address 1

Address 2

City/Town

Postal/Zip Code

Country

License Type

Your Inquiry *

CAPTCHA

This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Drug Pipeline

Pharma & Healthcare

*Please note that the report cover image shown above is for representation purpose only. Actual report cover may vary.

听

Related 麻豆原创 Research Reports

Publication	Price
Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective This report provides you with a landscape description and analysis of degrader-antibody conjugate (DAC) stakeholders, platform technologies, development and discovery pipelines and partnering deals from an industry perspective as of September 2024. The emerging novel drug modality of degrader-antibody conjugates represents the convergence of the existing technologies of antibody-drug conjugation and targeted protein degradation to combine the strengths and avoid the limitations of both technologies. DACs combine the specificity of antibodies with the efficiency of degraders of difficult-to-drug protein targets. Degrader-antibody conjugates provide plenty of opportunities for ADC companies to use a novel payload to improve efficacy and the therapeutic window and for targeted protein degradation (TPD) companies to improve cell-specificity, half-life, and drug-like properties. The two main uses for Degrader-Antibody Conjugate therapy...Read more	USD 2,300.00
Antibody Target, Technology & Pipeline Database: 1-Year Subscription Subscription to听La Merie Publishing's听proprietary Antibody Database provides online access to information about more than 6,231 project entries for therapeutic antibodies on the market and in research & development. Pre-established and free search functions allow to identify antibodies according to their Technology听(e.g. antibody-drug conjugate, bispecific, isotype, phage display) Target听(e.g. Her2, CD20, PD-1/PD-L1, CLDN18) Pipelines听(selected by target, therapeutic area, company, technology) Sales听(for marketed antibodies) R&D Phase听(clinical phases, market, preclinical) Territory听(countrywise) Therapeutic Area听(e.g. infectious, ...Read more	USD 1,760.00
Claudin 18.2 - Targeted Immunotherapy: A Landscape Analysis of Stakeholders, Drug Modalities, Pipeline and Business Opportunities from an Industry Perspective This report provides you with a landscape description and analysis of discovery and development of claudin 18.2 (CLDN18.2)-targeted antibody and cell therapy candidates from an industry perspective as of August 2023. CLDN18.2 is transmembrane protein selectively expressed on the cancer cell surface of gastric epithelial cells. The report brings you up-to-date with information about and analysis of Claudin 18.2 target identification and validation; Differential expression profile of claudin 18.2 in health and tumor tissues; Incidence of cancers with significant expression of claudin 18.2 in major countries; Scope and economic terms of licensing agreements for anti-CLDN18.2 immunotherapy candidates and discovery technologies; Stakeholders in the field: major pharma and biotech, ex-China biotech companies; Chinese major pharma and Chinese emerging biopharma companies; Specific company profiles, especially of Chinese,...Read more	USD 2,365.00
CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing This report provides a landscape description and analysis of chimeric antigen receptor-macrophage (CAR-M) platform technologies and stakeholders from an industry perspective as of February 2023. CAR-M cell therapy is an approach to overcome the limitations and obstacles of CAR T-cell and CAR natural killer (NK) cell therapy. CAR macrophages bring several unique benefits. CAR macrophages can effortlessly submerge in the cancer environment. Additionally, CAR-macrophages can decrease the ratio of tumor-associated macrophages (TAMs) and switch the phenotype of TAMs. Moreover, CAR macrophages play a phagocytic role in tumor cells, facilitate antigen presentation, and augment the cytotoxicity of T cells. Finally, CAR-macrophages have less toxicity and limited circulation time than T cells. Two main approaches for CAR-M cell therapy are: Autologous CAR-M cell therapy with ex vivo manufacturing or in vivo engineering of ...Read more	USD 2,000.00
Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report 'SerineThreonine Protein Kinase A Raf - Drugs In Development, 2022'; Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) pipeline Target constitutes close to 6 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Serine/threonine-protein kinase A-Raf is an enzyme that in humans is encoded by the ARAF gene. It is involved in the transduction of mitogenic signals from the cell membrane to the nucleus. It regulates the TOR signaling cascade. The report '...Read more	USD 3,500.00

Clients Who Trust Us

Need tailor made market research solution? We can help you with that too.

Contact Us

About Us

At 麻豆原创 we aim to make it easier for decision makers to find relevant information and locate right market research reports which can save their time and assist in what they do best, i.e. take time-critical decisions.

We work with our associate Global market research firms who are known leaders in their respective domains to obtain right market research solution for our customer鈥檚 needs, be it custom research or syndicated research reports.

Contact Us

麻豆原创 Research Reports, Inc
16192 Coastal Hwy
Lewes, DE 19958, USA

USA: +1-302-703-9904

India: +91-8762746600

marketresearchreports

info@marketresearchreports.com

Latest Blog Posts

Stay Connected

Disclaimer: 麻豆原创 has no affiliation to, and is not associated with any other website(s) or organization(s). We offer syndicated research reports (like country analysis, SWOT analysis, competitive intelligence, industry reports, company reports and market analysis & trends reports) and custom market research from our website 麻豆原创ResearchReports.com only.

If you are looking for a market research solution for your research requirements, please begin your search using the search box on top of this page or use our chat system to speak to our market research consultants or directly write to us.

麻豆原创